Fondens primære formål er i overenstemmelse med § 1 at sikre videreførelsen af LEO Pharma A/S med dertil knyttede selskaber. Bestyrelsen kan foretage de henlæggelser, den finder rimelige, til konsolidering af fondet. Overskud herefter kan i det omfang, bestyrelsen finder det forsvarligt og eventuelt efter indstilling fra LEO Pharma A/S, anvendes til at yde støtte til forskning inden for områderne medicin, kemi og/eller farmaci.
| Year | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 2025 | 13.5 mia. | 3.5 mia. | 39.5 mia. | 21.1 mia. | 4121 | |
CVR: 11623336
Secondary names: LEO Pharma Forskningsfond in memoriam August Kongsted
Compared to 50.000 companies in Ikke-finansielle holdingselskaber
Comparison is based on industry median values
LEO FONDET has demonstrated a significant turnaround in financial health, achieving a remarkable revenue increase from 9.96 billion DKK in 2021 to 13.50 billion DKK in 2025, alongside a profit rebound from a loss of 5.25 billion DKK in 2022 to a profit of 3.46 billion DKK in 2025. The company's equity has also strengthened, rising from 17.91 billion DKK in 2024 to 21.09 billion DKK in 2025, indicating a solid capital position. Despite previous years of losses, the current trajectory suggests a robust recovery, positioning LEO FONDET favorably within the non-financial holding companies sector. However, the volatility in profit margins raises concerns about sustainability in the long term.
AI-generated summary
Adam Sinding Steensberg joined the board
Klaus Legau joined the board
Tina Sejersgård Fanø joined the board
Anne Krogh Gæmelke joined the board
Niels Højsager Bennike joined the board
Ole Malta Bigand joined the board
Karina Bjørk joined the board
Kasper Rafn joined the board
Heidi Holmstrup joined the board
Thomas Christian Facius left the board
Companies in the same industry and area
CVR 10370671
CVR 31065372
CVR 33596200
CVR 37033553
CVR 27130860
companydata.dk